ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1168

Evaluation of Biomarkers in Chronic Hemodialysis (HD) Patients Dialyzed with Optiflux High-Flux Dialyzers

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Zhou, Meijiao, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Ficociello, Linda, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Costanzo, Mark, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Mullon, Claudy, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Kossmann, Robert J., Fresenius Medical Care North America, Waltham, Massachusetts, United States
Background

Optiflux® (OPTI) dialyzers are single-use, high-flux dialyzers available in the following sizes: F160NR (1.5 m2), F180NR (1.7 m2), F200NR (1.9 m2), and F250NR (2.5 m2). They are designed to enhance small and middle molecule clearance without increasing albumin loss. Epidemiologic data has shown low serum albumin (sALB) to be a marker of increased mortality risk in dialysis patients (pts). Thus, loss of albumin should be avoided especially in pts with low sALB. This retrospective study aimed to assess changes in biomarkers in pts dialyzed with Optiflux dialyzers for 6 months, including a subset of pts with low sALB levels at baseline.

Methods

976 in-center HD pts treated exclusively with Optiflux dialyzers for 6 months without liver disease, cancer, HIV, or history of drug abuse were analyzed in this study. Pre-HD labs at the first month of data collection (M1) and Month 6 (M6) were compared using paired t-test. A sub-analysis of pts with hypoalbuminemia (sALB ≤3.5mg/dL) at M1 was conducted. All analyses were performed separately for each dialyzer. Pts dialyzed with F200NR and F250NR were combined into 1 group.

Results

Mean biomarker levels during M1 and M6 are presented for the dialyzer groups (table). Most notably, significant increases of mean sALB and hemoglobin were observed in all groups. In the sub-analysis of pts with hypoalbuminemia at M1 (n=156), 87% of pts had increases in sALB by M6 (48/59=81.4% in F160NR, 82/92=89.1% in F180NR, and 5/5=100% in F200NR and F250NR) and 53.8% (84/156) achieved sALB >3.5 g/dL at M6.

Conclusion

During a 6-month follow-up, HD patients dialyzed with Optiflux dialyzers showed increases in serum albumin and hemoglobin while maintaining dialysis adequacy.

  Serum albumin
(g/dL)
Hgb
(g/dL)
spnPCR
(g/kg/day)
UFV
(L)
spKt/V
F160NR
(n=310)
M13.8010.661.032.131.80
M63.8911.051.072.201.81
Difference0.090.390.040.060.02
p-value<0.0001<0.00010.010.080.36
F180NR
(n=634)
M13.8610.821.032.561.64
M63.9111.081.072.621.69
Difference0.050.260.040.060.05
p-value<0.0001<0.00010.00060.030.002
F200NR and F250NR
(n=32)
M13.8210.911.103.651.54
M63.9311.281.053.561.54
Difference0.110.37-0.06-0.09-0.005
p-value0.020.030.050.400.87

Sp= single pool; nPCR = normalized protein catabolic rate; UFV= ultrafiltration volume

Funding

  • Commercial Support